Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Waleed Ghanima, Howard A. Liebman, Yu Hu, Yoshitaka Miyakawa, Nichola Cooper, Güray Saydam, Marie Luise Hütter-Krönke, Sylvain Audia, Mengjie Yao, Ahmed Daak, Imene Gouia, Matias Cordoba, David J Kuter

Blood (2024) 144 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2024-200279

Published: 2024

Journal Articles

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Blood (2024) 144 (Supplement 1): 5.

https://doi.org/10.1182/blood-2024-199718

Published: 2024

Journal Articles

Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia

Waleed Ghanima, Nichola Cooper, Sylvie Bozzi, Ahmed Daak, Imene Gouia, Matias Cordoba, Javier Barrio, Michael Kostikas, Owen Cooper, Howard A. Liebman

Blood (2023) 142 (Supplement 1): 2379.

https://doi.org/10.1182/blood-2023-179124

Published: 2023

Journal Articles

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Eun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer DiRaimo, Terry Gernsheimer, Alexandra Kruse, Craig Kessler, Caroline Kruse, Andrew D. Leavitt, Alfred I. Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D. Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B. Bussel

Blood (2022) 139 (10): 1564–1574.

https://doi.org/10.1182/blood.2021013411

Published: 2022

Includes: Supplemental data

Journal Articles

Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study

Hanny Al-Samkari, Debbie Jiang, Terry B. Gernsheimer, Howard A. Liebman, Susie Lee, Chelsea Bernheisel, Scott Kolodny, Matthew Wojdyla, Michael Vredenburg, Brian Jamieson, Adam Cuker

Blood (2021) 138 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2021-151321

Published: 2021

Journal Articles

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Eun-Ju Lee, Marina Beltrami Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer MacWhirter - DiRaimo, Terry B. Gernsheimer, Alexandra Kruse, Craig M. Kessler, Caroline Kruse, Andrew D Leavitt, Alfred Ian Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B Bussel

Blood (2021) 138 (Supplement 1): 586.

https://doi.org/10.1182/blood-2021-152918

Published: 2021

Journal Articles

Are Tpo agonists an option for ITP in pregnancy?

Howard A. Liebman

Blood (2020) 136 (26): 2971–2972.

https://doi.org/10.1182/blood.2020008637

Published: 2020

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Adrian C. Newland, Howard A. Liebman, MD, Vickie McDonald, MD, Marc Michel, Yoshitaka Miyakawa, Wim Parys, MD, Hans De Haard, Peter Ulrichts, Marie Godar, Kristof De Beuf, Jaume Ayguasanosa, Catherine M Broome, David J. Kuter, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141161

Published: 2020

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

https://doi.org/10.1182/blood-2019-128022

Published: 2019

Journal Articles

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Blood (2018) 132 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood-2018-120738

Published: 2018

Journal Articles

Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)

Jeffrey I. Zwicker, MD, Benjamin L. Schlechter, MD, Jack Davis Stopa, PhD, Howard A. Liebman, MD, Anita Aggarwal, PhDDO, Thomas Caughey, MD, Ken A. Bauer, MD, Nancy Kuemmerle, D.O., Ellice Y. Wong, MD, Ted Wun, MD, Marilyn Mclaughlin, MD, Maneka Puligandla, MS, Donna S Neuberg, ScD, Bruce Furie, MD, Robert C. Flaumenhaft, MD PhD

Blood (2018) 132 (Supplement 1): 985.

https://doi.org/10.1182/blood-2018-99-114946

Published: 2018

Journal Articles

Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study

Davendra P. S. Sohal, MD MPH, Nicole M. Kuderer, MD, Frances A. Shepherd, MD FRCPC, Ingrid Pabinger, Prof, Giancarlo Agnelli, MD, Howard A. Liebman, MA, MD, Eric Vicaut, MD, Guy Meyer, MD, Gary H. Lyman, MD MPH, Alok A. Khorana, MD

Blood (2016) 128 (22): 1422.

https://doi.org/10.1182/blood.V128.22.1422.1422

Published: 2016

Journal Articles

Combination Treatment of Rituximab, Cyclophosphamide, and Dexamethasone for Warm Autoimmune Hemolytic Anemia

Hillel Bocian, MD, Caroline Piatek, MD, Howard A Liebman, MD, Casey L O'Connell, MD, Ilene Ceil Weitz, MD, Cage Saul Johnson, MD

Blood (2016) 128 (22): 4802.

https://doi.org/10.1182/blood.V128.22.4802.4802

Published: 2016

Journal Articles

Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy

Nicole M. Kuderer, MD, Marek S. Poniewierski, MD MS, MS, Eva Culakova, PhD MS, Gary H. Lyman, MD MPH, Alok A. Khorana, MD, Ingrid Pabinger, Prof, Giancarlo Agnelli, MD, Howard A. Liebman, MA, MD, Eric Vicaut, MD, Guy Meyer, MD, Frances A. Shepherd, MD FRCPC

Blood (2016) 128 (22): 3590.

https://doi.org/10.1182/blood.V128.22.3590.3590

Published: 2016

Journal Articles

Life-Threatening Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Effective Treatment with Eculizumab Followed By Rituximab

Ilene C Weitz, MD, Mark Boonyasampant, MD, Brian Kay, MD, Chaiyaporn Boonchalervichian, MD, Howard A. Liebman, MA, MD, Ira A. Shulman, MD

Blood (2014) 124 (21): 4286.

https://doi.org/10.1182/blood.V124.21.4286.4286

Published: 2014

Journal Articles

Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma

Sikander Ailawadhi, M.D., Howard A Liebman, MD, Susan Groshen, PhD, Denice D. Tsao-Wei, PhD, Leanne Rochanda, MS, Ibrahim Aldoss, MD, Casey O'Connell, MD, Teresa Wang, Christine Duran, Frederick Rickles, MD, FACP

Blood (2013) 122 (21): 5350.

https://doi.org/10.1182/blood.V122.21.5350.5350

Published: 2013

Journal Articles

D-Dimer Levels Among Cancer Patients with Unsuspected Pulmonary Embolism: Clinical Correlates and Relevance

Sonia Ali, MD, Elizabeth Dilday, Scott Tagawa, MD, Naveed H. Akhtar, MD, Howard A Liebman, MD, Pedram Razavi, MD, PhD, Leanne Rochanda, MS, David I Quinn, MD, PhD, Kathleen Seaton, Casey L. O'Connell, MD

Blood (2012) 120 (21): 1154.

https://doi.org/10.1182/blood.V120.21.1154.1154

Published: 2012

Journal Articles

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Howard A. Liebman, MA, MD, Mansoor N Saleh, MD, James B. Bussel, MD, O George Negrea, MD, Heather Horne, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 622.

https://doi.org/10.1182/blood.V120.21.622.622

Published: 2012

Journal Articles

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Howard A Liebman, MD, Mansoor N Saleh, MD, James B Bussel, MD, Zale P Bernstein, MD, O George Negrea, MD, Anthony C Onyegbula, DO, Charles M Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2011) 118 (21): 3302.

https://doi.org/10.1182/blood.V118.21.3302.3302

Published: 2011

Journal Articles

The ITP syndrome: pathogenic and clinical diversity

Douglas B. Cines, James B. Bussel, Howard A. Liebman, Eline T. Luning Prak

Blood (2009) 113 (26): 6511–6521.

https://doi.org/10.1182/blood-2009-01-129155

Published: 2009

Includes: Supplemental data

NARROW

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Are Tpo agonists an option for ITP in pregnancy?

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)

Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study

Combination Treatment of Rituximab, Cyclophosphamide, and Dexamethasone for Warm Autoimmune Hemolytic Anemia

Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy

Life-Threatening Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Effective Treatment with Eculizumab Followed By Rituximab

Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma

D-Dimer Levels Among Cancer Patients with Unsuspected Pulmonary Embolism: Clinical Correlates and Relevance

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

The ITP syndrome: pathogenic and clinical diversity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only